Nicholas Simon
Overview
Explore the profile of Nicholas Simon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
56
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stewart T, Chalfin H, Simon N, Tan A, Apolo A, McKay R
Bladder Cancer
. 2024 Nov;
10(3):183-198.
PMID: 39493820
Muscle-invasive bladder cancer represents a potentially curable disease, yet often disease recurs and is ultimately fatal. Outcomes for patients with localized urothelial carcinoma are heterogeneous with some patients cured with...
2.
Apolo A, Ballman K, Sonpavde G, Berg S, Kim W, Parikh R, et al.
N Engl J Med
. 2024 Sep;
392(1):45-55.
PMID: 39282902
Background: Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive urothelial carcinoma after radical...
3.
Apolo A, Girardi D, Niglio S, Nadal R, Kydd A, Simon N, et al.
J Clin Oncol
. 2024 Jul;
42(25):3033-3046.
PMID: 38954785
Purpose: Cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) have shown promising efficacy and safety in patients with metastatic urothelial carcinoma (mUC), metastatic renal cell carcinoma (mRCC), and rare...
4.
Simon N, Atiq S, Sonpavde G, Apolo A
Urol Clin North Am
. 2024 Jun;
51(3):367-376.
PMID: 38925739
Penile cancer is a rare malignancy with a poor prognosis. Studies with single-agent immune checkpoint inhibitors (ICIs) have demonstrated efficacy, but response rates are low. Studies combining ICIs with both...
5.
El Zarif T, Nassar A, Pond G, Zhuang T, Master V, Nazha B, et al.
J Natl Cancer Inst
. 2023 Aug;
115(12):1605-1615.
PMID: 37563779
Background: Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with penile squamous cell carcinoma receiving immune checkpoint inhibitors....
6.
Apolo A, Msaouel P, Niglio S, Simon N, Chandran E, Maskens D, et al.
Am Soc Clin Oncol Educ Book
. 2022 May;
42:1-16.
PMID: 35609225
The role of adjuvant therapy in renal cell carcinoma and urothelial carcinoma is rapidly evolving. To date, the U.S. Food and Drug Administration has approved sunitinib and pembrolizumab in the...
7.
Yoshikawa G, Simon N, Nakasone R, Acoba J
J Gastrointest Cancer
. 2021 Jan;
53(1):144-150.
PMID: 33392961
Purpose: The incidence and prognosis of Pacific Islanders with gastric cancer is not well documented as previous studies have often aggregated this population with Asians. The purpose of our study...
8.
Abayomi O, Amato D, Bailey C, Bitanihirwe B, Bowen L, Burshtein S, et al.
Schizophr Res
. 2014 Oct;
159(2-3):e1-22.
PMID: 25306204
The 4th Schizophrenia International Research Society Conference was held in Florence, Italy, April 5-9, 2014 and this year had as its emphasis, "Fostering Collaboration in Schizophrenia Research". Student travel awardees...
9.
Simon N, Bochman M, Seguin S, Brodsky J, Seibel W, Schwacha A
Biosci Rep
. 2013 Sep;
33(5).
PMID: 24001138
Most currently available small molecule inhibitors of DNA replication lack enzymatic specificity, resulting in deleterious side effects during use in cancer chemotherapy and limited experimental usefulness as mechanistic tools to...